>
产品中心 >
Small_molecule >
Medchemexpress/Pasireotide二氟乙酸(同义词:SOM230二氟乙酸;帕西罗梯TFA盐)/HY-79135/5mg

Description | Pasireotide(ditrifluoroacetate)isastablecyclohexapeptidesomatostatinmimicthatexhibitsuniquehigh-affinitybindingtohumansomatostatinreceptors(subtypessst1/2/3/4/5,pKi=8.2/9.0/9.1/<7.0 .9,="" respectively).=""> |
---|---|
IC50&Target | pKi:8.2(sst1),9.0(sst2),9.1(sst3),<7.0 (sst4),="" 9.9=""> |
InVitro | Pasireotideeffectivelyinhibitsthegrowthhormonereleasinghormone(GHRH)inducedgrowthhormone(GH)releaseinprimaryculturesofratpituitarycellswithanIC50 of0.4±0.1nM[1]. |
InVivo | PasireotidepotentlysuppressessGHsecretioninrats.TheED50 valuesdeterminedat1and6hafterinjectionof pasireotideindicatesitsverylongdurationofactioninvivo.Intherat, pasireotide stronglydecreasesIGF-1plasmalevels,withtheefficacybeingmarkedlyenhancedcomparedwiththeeffectselicitedby SMS201-995 after7daysoftreatment.FurThermore,inrats,dogs,andrhesusmonkeys,pasireotidepotentlyanddose-dependentlydecreasesIGF-1levelsforprolongedperiodsoftimewithoutdesensitization[1].Pasireotide(160mg/kg/month,s.c.)decreasesseruminsulinlevelsandincreasesserumglucoselevels,reducesPNETtumorsize,anddemonstratesareductionintumoractivityonPET/CTscaninPdx1-Cre;Men1floxed/floxedconditionalknockoutmice[2].Pasireotide(50μg/kg)inhibitsarthriticjointswellinginadose-dependentmanner,stronglyinhibitsjointswellingduringtheacutephaseofAIA.Pasireotide-andoctreotide-treatedmiceshowsignificantlyincreasedmechanicalthresholdsontheinflamedside.Pasireotidepotentlydecreasessecondaryhyperalgesiatomechanicalandthermalstimuli.Mechanicalthresholdsinthepasireotide-treatedmicearesignificantlyhigherthanthoseinthesaline-treatedoroctreotide-treatedanimals[3]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AnimalAdmiNISTration [1] | Pasireotideisformulatedinsaline. Miceareanesthetizedusinghalothaneandthenshavedontheirflankforsubcutaneousinjectionofeitherphosphatebufferedsaline(PBS)bufferorPasireotideataconcentrationof160mg/Kg/month(64mg/mL)everymonthfor4months.Themiceunderwenta24-hfastpriortocollectingwholebloodviaaretro-orbitalbleedingtechniqueweeklyatpre-andpost-treatments.SerumglucoseismeasuredbyenzymaticcolorimetricassayusingaGM7Analyzer.Seruminsulinismeasuredbyenzyme-linkedimmunosorbentassay(ELISA)withtheUltrasensitiveMouseInsulinELISAkitaccordingtothemanufacturer’sinstructions.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
References |
|
MolecularWeight | 1275.25 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₆₂H₆₈F₆N₁₀O₁₃ | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | 10mMinDMSO *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation=""> Purity:99.51% |